Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector
- PMID: 20409441
- PMCID: PMC2859794
- DOI: 10.15288/jsad.2010.71.460
Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector
Abstract
Objective: The U.S. substance-abuse treatment system has been slow to adopt medications for the treatment of alcohol-use disorders (AUDs). The objectives of this study are to (a) determine how the inherent characteristics of injectable naltrexone (i.e., relative advantage, complexity, trialability, observability, compatibility) shape organizational-level decisions to adopt the medication and (b) identify key predictors of adoption and barriers that impede adoption.
Method: This study uses data from a nationally representative sample of 345 privately funded U.S. substance-abuse treatment programs to examine adoption (current use) of injectable naltrexone.
Results: Sixteen percent of private treatment programs are early adopters of injectable naltrexone. Multivariate logistic regression models reveal that organizational size and percentage of patients paying with private insurance are significant predictors of adoption. The most salient predictor of adoption is innovation compatibility, measured by program use of other AUD pharmacotherapies. Barriers to adoption include cost, lack of access to prescribing physicians, and lack of knowledge about the medication. Injectable naltrexone, however, is addressing the patient compliance barrier, demonstrated by 70% of patients receiving at least 2 months of medication.
Conclusions: The adoption of AUD pharmacotherapies remains low, with only half of the sampled programs prescribing any AUD pharmacotherapies. Patterns of early adoption of injectable naltrexone are, however, promising. Results highlight innovation compatibility and relative advantage as explanations of organizational decisions to adopt injectable naltrexone. Future research will move beyond issues of adoption and provide a more detailed examination of the implementation process.
References
-
- Agency for Health Care Policy and Research. Pharmacotherapy for alcohol dependence (Evidence report/technology assessment no. 3, AHCPR Publication No. 99-E004) Rockville, MD: Author; 1999.
-
- Center for Substance Abuse Treatment. Naltrexone and alcoholism treatment. (Treatment Improvement Protocol [TIP] Series 28, DHHS Publication No. [SMA] 98-3206) Rockville, MD: Substance Abuse and Mental Health Services Administration; 1998. - PubMed
-
- Ducharme LJ, Knudsen HK, Roman PM. Trends in the adoption of medications for alcohol dependence. Journal of Clinical Psychopharmacology. 2006;26(Suppl. No. 1):S13–S19. - PubMed
-
- Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment. 2005;28:273–280. - PubMed
-
- Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Ehrich EW. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. Journal of the American Medical Association. 2005;293:1617–1625. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources